Alembic Pharmaceuticals today reported a 29.64 per cent rise in consolidated net profit at Rs 91.18 crore for the quarter ended March 31.
It had posted a profit of Rs 70.33 crore for the similar period of the previous fiscal, Alembic Pharmaceuticals said in a BSE filing.
The company's consolidated total income from operations rose 24.57 per cent to Rs 626.57 crore for the quarter under review as against Rs 502.98 crore a year ago.
For the full fiscal, the consolidated profit increased by 154.28 per cent to Rs 719.44 crore as against Rs 282.93 crore in 2014-15.
Consolidated total income grew 53.13 per cent to Rs 3,148.71 crore in 2015-16 fiscal as against Rs 2,056.12 crore.
"This has been an outstanding year for the company. R&D will continue to be a thrust area and we hope to strengthen our portfolio rapidly in years to come," Parana Amin Managing Director of Alembic Pharma said.
In a separate filing, the company said the board has recommended a dividend of Rs 4 per equity share.
Besides, the board has appointed Chirayu Amin as the Executive Chairman and Chief Executive Officer of the company, with effect from today. It has also appointed Pranav Amin and Shaunak Amin as managing directors.
